Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt (Q48532745)
scientific article published in February 1998
Language:
Current Data About Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt
(P31) (Q13442814)
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

(P304) 350-355
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

(P407) (Q1860)

(P433) 4
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

(P478) 97
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

(P577) Sunday, February 1, 1998
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

(P921) (Q181600)

(Q18216)
(P887)

(Q1266890)
(P887)

(P1433) (Q578091)
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

(P1476) "Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt" (language: en)
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

(P2093) Valles J
(P1545) 1
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

Santos MT
(P1545) 2
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

Aznar J
(P1545) 3
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

Osa A
(P1545) 4
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

Lago A
(P1545) 5
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

Cosin J
(P1545) 6
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

Sanchez E
(P1545) 7
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

Broekman MJ
(P1545) 8
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

Marcus AJ
(P1545) 9
(P248)
(P698) 9468208
(P813) Monday, February 12, 2018
(P854) http://europepmc.org/abstract/MED/9468208

other details
description scientific article published in February 1998

External Links
(P356) 10.1161/01.CIR.97.4.350
(P698) 9468208
(P5875) 13763093